Table 1 Descriptive characteristics of the study population

Patients, n

151

74

NA

Age, yr,

(median; IQR)

63.5; 65–74

64.9;62–73

0.26

tPSA, ng/ml,

(median; IQR)

5.7; 4.8–6.7

5.3; 4.2–6.6

0.30

fPSA, ng/ml,

(median; IQR)

1.12; 0.41–3.39

1.16; 0.32–4.17

0.21

PSA f/t,

(median; IQR)

0.13; 0.06–0.44

0.17; 0.09–0.52

0.16

MRI-based PV, cm³

(median; IQR)

46.2; 36.4–59.4

48.2; 33.7–58.1

0.32

Adjusted PSAD, ng/ml/cm3, mean (median; IQR)

0.17; 0.12–0.53

0.16; 0.06–0.47

0.71

DRE nodules

yes/no, n (%)

86 (57) / 65 (43)

44 (59) / 30 (41)

0.46

TRUS,

Hypoechoic (positive)/Isoechoic (negative)

81 (53) / 70 (47)

42 (56) / 32 (44)

0.56

PI-RADS v2 scores, mean (± SD)

3.3 (±0.9)

3.1 (±1.0)

0.50

Pathological outcomes, n (%)

High-grade cancer

32 (21)

18 (24)

0.80

Low-grade cancer

52 (35)

20 (28)

Benign

67 (44)

36 (48)